Hello, everyone, and welcome to the middle of the week. Already, you say? Well, the world keeps spinning, after all, despite the sometimes numbing developments out there. So time to get cracking. We are firing up the coffee kettle for another cup of stimulation — cinnamon dolce is our choice today — and foraging for items of interest. On that note, here are a few tidbits to get your started. We hope your journey today is calm and productive. And as always, do keep in touch. We enjoy your tips, ideas, and secrets. …

The Food and Drug Administration is expected to spell out a tough, new standard for an emergency authorization of a Covid-19 vaccine as soon as this week that will make it difficult for any vaccine to be cleared before Election Day, The Washington Post reports. The agency is issuing the guidance to boost transparency and public trust as it approaches the momentous decision of whether a prospective vaccine is safe and effective. Public health experts are increasingly worried that President Trump’s repeated predictions of a vaccine by Nov. 3, coupled with administration interference in federal science agencies, may prompt Americans to reject any vaccine as rushed and potentially tainted.

A federal vaccine advisory committee will delay a vote on recommending who should get initial limited doses of any Covid-19 vaccine in the U.S. until learning more about the vaccines that could become available first, The Wall Street Journal reports. The Advisory Committee on Immunization Practices, a group of external medical experts that advises the Centers for Disease Control and Prevention, was initially expected to vote at a meeting Tuesday on a plan to give priority to initial doses of any vaccine that passes muster in clinical trials. The ACIP may wait until government officials authorize a specific vaccine for use before voting on how to give priority to initial doses.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy